Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Altman Z2-Score is 5.85 as of Jul. 14, 2026, which is at its 10-year median of 5.85. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 83.76% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Cellyan Biotechnology Co has a Altman Z2-Score of 5.85, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Cellyan Biotechnology Co's Altman Z2-Score or its related term are showing as below:
HKPD'
s Altman Z2-Score Range Over the Past 10 Years
Min: 2.85 Med: 5.85 Max: 6.34
Current: 5.85
During the past 3 years, Cellyan Biotechnology Co's highest Altman Z2-Score was 6.34. The lowest was 2.85. And the median was 5.85.
Cellyan Biotechnology Co (NAS:HKPD) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKPD vs COSM, SNYR, YI: Altman Z2-Score Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Altman Z2-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Altman Z2-Score falls into.
Cellyan Biotechnology Co Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Cellyan Biotechnology Co (HKPD) has a Altman Z2-Score of 5.85 as of Jul. 14, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Cellyan Biotechnology Co and its competitors. This is near median its historical median of 5.85. Over the past decade, Cellyan Biotechnology Co's Altman Z2-Score has ranged from 2.85 to 6.34. According to the industry distribution chart, Cellyan Biotechnology Co ranks #19 out of 117 companies in the Medical Distribution industry, placing it in the top 16.2%.
Is Cellyan Biotechnology Co's Altman Z2-Score too high?
Cellyan Biotechnology Co's current Altman Z2-Score of 5.85 is near median its 10-year median of 5.85. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 6.34. The Medical Distribution industry median Altman Z2-Score is 2.77. Cellyan Biotechnology Co's value of 5.85 is 111.2% above this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #19 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Altman Z2-Score compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #19 out of 117 companies for Altman Z2-Score. This places Cellyan Biotechnology Co in the top 16% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 2.77. Cellyan Biotechnology Co's value of 5.85 is 111.2% above this benchmark. Historically, Cellyan Biotechnology Co's own Altman Z2-Score has ranged from 2.85 to 6.34 over the past decade. While the company's 10-year median is 5.85 vs. the industry median of 2.77, Cellyan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Distribution company?
The median Altman Z2-Score among Medical Distribution companies is 2.77, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Altman Z2-Score of 5.85 is 111.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Altman Z2-Score is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Altman Z2-Score is 5.85, which is near median its own 10-year median of 5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Altman Z2-Score of 5.85. The current Altman Z2-Score is 5.85, which is near median its 10-year median of 5.85 and 111.2% above the Medical Distribution industry median of 2.77. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Altman Z2-Score is 5.85 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
